AstraZeneca PLC - AZN StarRatingValueLabel_3Jay Lee - Senior Equity Analyst - Morningstar Inc.

Last Price
11,392.00
Day Change
0.00|0.00%

As of 04/04/2025
16:11:20 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
10,876.00 - 10,880.0010,812.00 - 11,342.001,071,4102,706,733176.60Bil
Last Close52 Week RangeP/EYield %ISIN
11,392.009,670.00 - 13,388.0033.022.16GB0009895292

Morningstar's Take AZN

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets up solid long-term growth.

Fair Value Estimate

Premium

Uncertainty

Premium

Economic Moat

Premium

Financial Strength

Financial Strength
There is no one analyst in which a Quantitative Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here.

Total Returns 03/04/2025

 Chg (%)  
AstraZeneca PLC-4.30 
FTSE 100 TR GBP-3.90
 
Financials
202220232024
more...
Income Statement
Turnover44,351.0045,811.0054,073.00
Operating Profit4,512.008,722.0010,251.00
Net Profit3,293.005,961.007,041.00
Reported EPS2.113.814.50
Balance Sheet
Current Assets22,443.0025,054.0025,827.00
Non Current Assets73,890.0076,065.0078,208.00
Total Assets96,483.00101,119.00104,035.00
Current Liabilities26,293.0030,542.0027,866.00
Total Liabilities59,425.0061,953.0063,164.00
Total Equity37,058.0039,166.0040,871.00
Cash Flow
Operating Cash Flow11,431.0012,711.0014,611.00
Net Change in Cash25.00-286.00-115.00

Regulatory News

DateAuthor Headline
18/11/2024Christopher Johnson The 5 Stocks Dragging The FTSE 100 Down
AstraZeneca, Persimmon and Schroders among recently struggling stocks.
06/11/2024Christopher Johnson Can The GRANOLAS Stocks End 2024 On A High?
Amid market volatility and falling interest rates, Europe‘s Magnificent Seven have delivered a mixed performance, but this could all change.
25/09/2024Christopher Johnson Could The FTSE 100 Hit Another Record High in Q4?
The FTSE 100 has had a strong 2024, reaching record highs in May. But can the UK's blue-chip index pull off another record before the 'Santa' rally arrives?
Director Dealings
TradedActionNotifierPriceAmountValue
more...
06/03/2025Transfer inMr. Pascal Soriot0.0089,9620.00
05/03/2025DMr. Pascal Soriot0.002480.00
05/03/2025DDr. Aradhana Sarin0.00280.00
04/03/2025Transfer inMr. Pascal Soriot0.0017,3570.00

Company Profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Sector

Healthcare

Industry

Drug Manufacturers - General

Stock Style

Large-Growth

Fiscal Year Ends

December

Employees

94,300

Next Event 11/04/2025

Annual General Meeting
Ratios
Comp
PER (E)32.35
Div Yld (E)2.18
PEG (E)1.03
ROCE13.62
Op Mrgn19.00
EPS Grwth0.12
Dividends
PreviousLatest
more...
Record Date09/08/2421/02/25
Ex-Div08/08/2420/02/25
Paid09/09/2424/03/25
Amnt77.60168.00
Directors
more...
Non-Executive DirectorMs. Sherilyn S. McCoy
Non-Executive DirectorDr. Andreas Rummelt
Non-Executive DirectorMr. Marcus Wallenberg
Non-Executive Director, ChairmanMr. Michel Demare
Executive Director, Chief Executive OfficerMr. Pascal Soriot
Non-Executive Director, Senior Independent DirectorMr. Philip A J Broadley
Non-Executive DirectorMs. Diana Layfield
Non-Executive DirectorMs. Deborah DiSanzo
Non-Executive DirectorMs. Anna Olive Magdelene Manz
Non-Executive DirectorProfessor Nazneen Rahman
Executive Director, Chief Financial OfficerDr. Aradhana Sarin
Non-Executive DirectorProfessor Tony Mok
Non-Executive DirectorDr. Euan Ashley
Jay Lee - Senior Equity Analyst - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures